ESCAPE Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.escapebio.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
Terminated
- Conditions
- Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Escape Bio, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05349019
- Locations
- 🇺🇸
Science 37, Culver City, California, United States
Parkinson's Disease G2019S LRRK2 Genetic Testing Program
Terminated
- Conditions
- Parkinson's Disease
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Escape Bio, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT04919356
- Locations
- 🇺🇸
Eurofins Genomic LLC, Louisville, Kentucky, United States
News
No news found